Marble Wealth LLC Acquires New Holdings in Amgen Inc. $AMGN

Posted by Brenda Bartman on Jun 4th, 2026

Marble Wealth LLC acquired a new stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 1,891 shares of the medical research company’s stock, valued at approximately $619,000.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Norges Bank acquired a new stake in Amgen in the fourth quarter worth about $2,164,162,000. Capital World Investors boosted its holdings in Amgen by 11.5% in the third quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock worth $5,303,578,000 after acquiring an additional 1,935,876 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Amgen by 7.8% in the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after acquiring an additional 1,035,779 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Amgen by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after acquiring an additional 961,975 shares in the last quarter. Finally, National Bank of Canada FI boosted its holdings in Amgen by 237.7% in the third quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock worth $346,076,000 after acquiring an additional 863,216 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Wells Fargo & Company raised their price target on Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a report on Thursday, March 19th. UBS Group raised their price target on Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Argus lowered their price target on Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a report on Wednesday, May 20th. Cantor Fitzgerald reissued a “neutral” rating and issued a $350.00 price target on shares of Amgen in a report on Wednesday, April 8th. Finally, Wall Street Zen raised Amgen from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $355.19.

Get Our Latest Stock Report on Amgen

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.85% of the stock is owned by company insiders.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

Positive Sentiment: Amgen secured European Commission approval for Imdylltra in a lung cancer indication, strengthening the drug’s commercial outlook and validating its clinical profile. EC approval for Amgen’s Imdylltra
Positive Sentiment: Amgen also announced new data presentations at the EULAR 2026 conference for rare autoimmune and inflammatory diseases, including longer-term safety and efficacy data for UPLIZNA and TAVNEOS, which may support these products’ market positioning. AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
Positive Sentiment: Another report highlighted analyst commentary on Amgen, which can reinforce investor confidence if recent updates are viewed favorably by the market. Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Thermo Fisher (TMO)
Neutral Sentiment: A feature story noted Amgen’s early adoption of AI under CEO Bob Bradway, underscoring the company’s push to improve research productivity, though it is not an immediate financial catalyst. The CEO who loves AI autodidacts — and desperately needs his experts

Amgen Stock Up 3.0%

Shares of AMGN stock opened at $338.22 on Thursday. The stock has a 50 day moving average of $341.49 and a 200 day moving average of $345.38. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The stock has a market cap of $182.54 billion, a P/E ratio of 23.54, a P/E/G ratio of 3.29 and a beta of 0.42. Amgen Inc. has a twelve month low of $267.83 and a twelve month high of $391.29.

Amgen (NASDAQ:AMGN – Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $4.77 by $0.38. The company had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.Amgen’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period last year, the business earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, sell-side analysts expect that Amgen Inc. will post 22.38 EPS for the current year.

About Amgen

(Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.